E-Z-EM announced Aug. 19 a common stock dividend of 9.2 million shares for its subsidiary AngioDynamics. The dividend, payable on Oct. 30 to E-Z-EM shareholders of record on Oct. 11, will mark AngioDynamics' debut as a separate company. The announcement
E-Z-EM announced Aug. 19 a common stock dividend of 9.2 million shares for its subsidiary AngioDynamics. The dividend, payable on Oct. 30 to E-Z-EM shareholders of record on Oct. 11, will mark AngioDynamics' debut as a separate company. The announcement came after E-Z-EM received a ruling from the IRS confirming that the dividend would be free from federal income taxes to E-Z-EM and its stockholders, except for any cash received by stockholders instead of a fractional share. AngioDynamics designs, develops, manufactures, and markets medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.